Engineering bacterial vectors for delivery of genes and proteins to antigen-presenting cells

Molecular Pharmaceutics

Volumn 4, Issue 1, 2007, Pages 4-17

  Parsa, Saba ^a   Pfeifer, Blaine ^a  

^a Tufts University   (United States)

Author keywords

Antigen presenting cells; Escherichia coli; Gene and protein delivery; Listeria; Salmonella; Shigella

Indexed keywords

BACTERIAL VECTOR; GENE THERAPY AGENT; LISTERIOLYSIN O; UNCLASSIFIED DRUG;

ANTIGEN PRESENTING CELL; BACTERIAL CELL; BACTERIAL STRAIN; DRUG DELIVERY SYSTEM; ESCHERICHIA COLI; GENE TARGETING; GENE VECTOR; HUMAN; IMMUNOSTIMULATION; LISTERIA; NONHUMAN; PRIORITY JOURNAL; REVIEW; SALMONELLA;

ANIMALS; ANTIGEN-PRESENTING CELLS; DNA, BACTERIAL; GENE TRANSFER TECHNIQUES; GENETIC ENGINEERING; GENETIC VECTORS; HUMANS;

EID: 33847204617     PISSN: 15438384     EISSN: 15438392     Source Type: Journal    
DOI: 10.1021/mp0600889     Document Type: Review

References (181)

1. Reis e Sousa, C.; Stahl, P. D.; Austyn, J. M. Phagocytosis of antigens by Langerhans cells in vitro. J. Exp. Med. 1993, 178 (2), 509-19.
2. Hemmi, H.; Takeuchi, O.; Kawai, T.; Kaisho, T.; Sato, S.; Sanjo, H.; Matsumoto, M.; Hoshino, K.; Wagner, H.; Takeda, K.; Akira, S. A Toll-like receptor recognizes bacterial DNA. Nature 2000, 408 (6813), 740-5.
3. Merrell, M. A.; Ilvesaro, J. M.; Lehtonen, N.; Sorsa, T.; Gehrs, B.; Rosenthal, E.; Chen, D.; Shackley, B.; Harris, K. W.; Selander, K. S. Toll-Like Receptor 9 Agonists Promote Cellular Invasion by Increasing Matrix Metalloproteinase Activity. Mol. Cancer Res. 2006, 4 (7), 437-47.
4. Roberts, T. L.; Dunn, J. A.; Terry, T. D.; Jennings, M. P.; Hume, D. A.; Sweet, M. J.; Stacey, K. J. Differences in macrophage activation by bacterial DNA and CpG-containing oligonucleotides. J. Immunol. 2005, 175 (6), 3569-76.
5. Takeuchi, O.; Hoshino, K.; Kawai, T.; Sanjo, H.; Takada, H.; Ogawa, T.; Takeda, K.; Akira, S. Differential roles of TLR2 and TLR4 in recognition of gram-negative and gram-positive bacterial cell wall components. Immunity 1999, 11 (4), 443-51.
6. Visser, L.; Jan de Heer, H.; Boven, L. A.; van Riel, D.; van Meurs, M.; Melief, M. J.; Zahringer, U.; van Strijp, J.; Lambrecht, B. N.; Nieuwenhuis, E. E.; Laman, J. D. Proinflammatory bacterial peptidoglycan as a cofactor for the development of central nervous system autoimmune disease. J. Immunol. 2005, 174 (2), 808-16.
7. Banchereau, J.; Steinman, R. M. Dendritic cells and the control of immunity. Nature 1998, 392 (6673), 245-52.
8. Matzinger, P. Tolerance, danger, and the extended family. Annu. Rev. Immunol. 1994, 12, 991-1045.
9. Paglia, P.; Medina, E.; Arioli, I.; Guzman, C. A.; Colombo, M. P. Gene transfer in dendritic cells, induced by oral DNA vaccination with Salmonella typhimurium, results in protective immunity against a murine fibrosarcoma. Blood 1998, 92 (9), 3172-6.
10. Joiner, K. A.; Goldman, R.; Schmetz, M.; Berger, M.; Hammer, C. H.; Frank, M. M.; Leive, L. A quantitative analysis of C3 binding to O-antigen capsule, lipopolysaccharide, and outer membrane protein of E. coli 0111B4. J. Immunol. 1984, 132 (1), 369-75.
11. Steinman, R. M. Dendritic cells and the control of immunity: Enhancing the efficiency of antigen presentation. Mt. Sinai J. Med. 2001, 68 (3), 160-6.
12. Luster, M. I.; Germolec, D. R.; Yoshida, T.; Kayama, F.; Thompson, M. Endotoxin-induced cytokine gene expression and excretion in the liver. Hepatology 1994, 19 (2), 480-8.
13. Mulligan, M. S.; Smith, C. W.; Anderson, D. C.; Todd, R. F., III; Miyasaka, M.; Tamatani, T.; Issekutz, T. B.; Ward, P. A. Role of leukocyte adhesion molecules in complement-induced lung injury. J. Immunol. 1993, 150 (6), 2401-6.
14. Lukacs, N. W.; Hogaboam, C.; Campbell, E.; Kunkel, S. L. Chemokines: Function, regulation and alteration of inflammatory responses. Chem. Immunol. 1999, 72, 102-20.
15. Qureshi, S. T.; Gros, P.; Malo, D. The Lps locus: Genetic regulation of host responses to bacterial lipopolysaccharide. Inflamm. Res. 1999, 48 (12), 613-20.
16. Hiemstra, P. S.; Eisenhauer, P. B.; Harwig, S. S.; van den Barselaar, M. T.; van Furth, R.; Lehrer, R. I. Antimicrobial proteins of murine macrophages. Infect. Immun. 1993, 61 (7), 3038-46.
17. Bone, R. C. The pathogenesis of sepsis. Ann. Intern. Med. 1991, 115 (6), 457-69.
18. Radford, K. J.; Higgins, D. E.; Pasquini, S.; Cheadle, E. J.; Carta, L.; Jackson, A. M.; Lemoine, N. R.; Vassaux, G. A recombinant E. coli vaccine to promote MHC class I-dependent antigen presentation: Application to cancer immunotherapy. Gene Ther. 2002, 9 (21), 1455-63.
19. Rescigno, M.; Valzasina, B.; Bonasio, R.; Urbano, M.; Ricciardi-Castagnoli, P. Dendritic cells, loaded with recombinant bacteria expressing tumor antigens, induce a protective tumor-specific response. Clin. Cancer Res. 2001, 7 (Suppl. 3), 865s-70s.
20. Schweichel, D.; Steitz, J.; Tormo, D.; Gaffal, E.; Ferrer, A.; Buchs, S.; Speuser, P.; Limmer, A.; Tuting, T. Evaluation of DNA vaccination with recombinant adenoviruses using bioluminescence imaging of antigen expression: Impact of application routes and delivery with dendritic cells. J. Gene Med. 2006, 8 (10), 1243-50.
21. Yrlid, U.; Svensson, M.; Johansson, C.; Wick, M. J. Salmonella infection of bone marrow-derived macrophages and dendritic cells: Influence on antigen presentation and initiating an immune response. FEMS Immunol. Med. Microbiol. 2000, 27 (4), 313-20.
22. Catic, A.; Dietrich, G.; Gentschev, I.; Goebel, W.; Kaufmann, S. H.; Hess, J. Introduction of protein or DNA delivered via recombinant Salmonella typhimurium into the major histocompatibility complex class I presentation pathway of macrophages. Microbes Infect. 1999, 1 (2), 113-21.
23. Dietrich, G.; Bubert, A.; Gentschev, I.; Sokolovic, Z.; Simm, A.; Catic, A.; Kaufmann, S. H.; Hess, J.; Szalay, A. A.; Goebel, W. Delivery of antigen-encoding plasmid DNA into the cytosol of macrophages by attenuated suicide Listeria monocytogenes. Nat. Biotechnol. 1998, 16 (2), 181-5.
24. Higgins, D. E.; Shastri, N.; Portnoy, D. A. Delivery of protein to the cytosol of macrophages using Escherichia coli K-12. Mol. Microbiol. 1999, 31 (6), 1631-41.
25. Svensson, M.; Stockinger, B.; Wick, M. J. Bone marrow-derived dendritic cells can process bacteria for MHC-I and MHC-II presentation to T cells. J. Immunol. 1997, 158 (9), 4229-36.
26. Fong, L.; Engleman, E. G. Dendritic cells in cancer immunotherapy. Annu. Rev. Immunol. 2000, 18, 245-73.
27. Gabrilovich, D. I.; Nadaf, S.; Corak, J.; Berzofsky, J. A.; Carbone, D. P. Dendritic cells in antitumor immune responses. II. Dendritic cells grown from bone marrow precursors, but not mature DC from tumor-bearing mice, are effective antigen carriers in the therapy of established tumors. Cell. Immunol. 1996, 170 (1), 111-9.
28. Gabrilovich, D. I.; Ciernik, I. F.; Carbone, D. P. Dendritic cells in antitumor immune responses. I. Defective antigen presentation in tumor-bearing hosts. Cell. Immunol. 1996, 170 (1), 101-10.
29. Giacalone, M. J.; Sabbadini, R. A.; Chambers, A. L.; Pillai, S.; McGuire, K. L. Immune responses elicited by bacterial minicells capable of simultaneous DNA and protein antigen delivery. Vaccine 2006, 24 (33-34), 6009-17.
30. Chart, H.; Smith, H. R.; La Ragione, R. M.; Woodward, M. J. An investigation into the pathogenic properties of Escherichia coli strains BLR, BL21, DH5α and EQ1. J. Appl. Microbiol. 2000, 89 (6), 1048-58.
31. Medina, E.; Guzman, C. A.; Staendner, L. H.; Colombo, M. P.; Paglia, P. Salmonella vaccine carrier strains: Effective delivery system to trigger anti-tumor immunity by oral route. Eur. J. Immunol. 1999, 29 (2), 693-9.
32. Keke, F.; Hongyang, Z.; Hui, Q.; Jixiao, L.; Jian, C. A combination of flk1-based DNA vaccine and an immunomodulatory gene (IL-12) in the treatment of murine cancer. Cancer Biother. Radiopharm. 2004, 19 (5), 649-57.
33. Sizemore, D. R.; Branstrom, A. A.; Sadoff, J. C. Attenuated Shigella as a DNA delivery vehicle for DNA-mediated immunization. Science 1995, 270 (5234), 299-302.
34. Cicin-Sain, L.; Brune, W.; Bubic, I.; Jonjic, S.; Koszinowski, U. H. Vaccination of mice with bacteria carrying a cloned herpesvirus genome reconstituted in vivo. J. Virol. 2003, 77 (15), 8249-55.
35. Shiau, A. L.; Chu, C. Y.; Su, W. C.; Wu, C. L. Vaccination with the glycoprotein D gene of pseudorabies virus delivered by nonpathogenic Escherichia coli elicits protective immune responses. Vaccine 2001, 19 (23-24), 3277-84.
36. Yrlid, U.; Svensson, M.; Hakansson, A.; Chambers, B. J.; Ljunggren, H. G.; Wick, M. J. In vivo activation of dendritic cells and T cells during Salmonella enterica serovar Typhimurium infection. Infect. Immun. 2001, 69 (9), 5726-35.
37. Paglia, P.; Terrazzini, N.; Schulze, K.; Guzman, C. A.; Colombo, M. P. In vivo correction of genetic defects of monocyte/macrophages using attenuated Salmonella as oral vectors for targeted gene delivery. Gene Ther. 2000, 7 (20), 1725-30.
38. Kawai, T.; Akira, S. TLR signaling. Cell Death Differ. 2006, 13 (5), 816-25.
39. Cossart, P.; Sansonetti, P. J. Bacterial invasion: The paradigms of enteroinvasive pathogens. Science 2004, 304 (5668), 242-8.
40. Schaffner, W. Direct transfer of cloned genes from bacteria to mammalian cells. Proc. Natl. Acad. Sci. U.S.A. 1980, 77 (4), 2163-7.
41. Blattner, F. R.; Plunkett, G., III; Bloch, C. A.; Perna, N. T.; Burland, V.; Riley, M.; Collado-Vides, J.; Glasner, J. D.; Rode, C. K.; Mayhew, G. F.; Gregor, J.; Davis, N. W.; Kirkpatrick, H. A.; Goeden, M. A.; Rose, D. J.; Mau, B.; Shao, Y. The complete genome sequence of Escherichia coli K-12. Science 1997, 277 (5331), 1453-74.
42. Hu, P. Q.; Tuma-Warrino, R. J.; Bryan, M. A.; Mitchell, K. G.; Higgins, D. E.; Watkins, S. C.; Salter, R. D. Escherichia coli expressing recombinant antigen and listeriolysin O stimulate class I-restricted CD8+ T cells following uptake by human APC. J. Immunol. 2004, 172 (3), 1595-601.
43. Critchley, R. J.; Jezzard, S.; Radford, K. J.; Goussard, S.; Lemoine, N. R.; Grillot-Courvalin, C.; Vassaux, G. Potential therapeutic applications of recombinant, invasive E. coli. Gene Ther. 2004, 11 (15), 1224-33.
44. Wick, M. J.; Pfeifer, J. D.; Findlay, K. A.; Harding, C. V.; Normark, S. J. Compartmentalization of defined epitopes expressed in Escherichia coli has only a minor influence on efficiency of phagocytic processing for presentation by class I and class II major histocompatibility complex molecules to T cells. Infect. Immun. 1993, 61 (11), 4848-56.
45. Brumell, J. H.; Perrin, A. J.; Goosney, D. L.; Finlay, B. B. Microbial pathogenesis: New niches for Salmonella. Curr. Biol. 2002, 12 (1), R15-7.
46. Grillot-Courvalin, C.; Goussard, S.; Courvalin, P. Wild-type intracellular bacteria deliver DNA into mammalian cells. Cell. Microbiol. 2002, 4 (3), 177-86.
47. Marra, A.; Isberg, R. R. Common entry mechanisms. Bacterial pathogenesis. Curr. Biol. 1996, 6 (9), 1084-6.
48. Grillot-Courvalin, C.; Goussard, S.; Courvalin, P. Bacteria as gene delivery vectors for mammalian cells. Curr. Opin. Biotechnol. 1999, 10 (5), 477-81.
49. Gallois, A.; Klein, J. R.; Allen, L. A.; Jones, B. D.; Nauseef, W. M. Salmonella pathogenicity island 2-encoded type III secretion system mediates exclusion of NADPH oxidase assembly from the phagosomal membrane. J. Immunol. 2001, 166 (9), 5741-8.
50. Garvis, S. G.; Beuzon, C. R.; Holden, D. W. A role for the PhoP/Q regulon in inhibition of fusion between lysosomes and Salmonella-containing vacuoles in macrophages. Cell. Microbiol. 2001, 3 (11), 731-44.
51. Kotton, C. N.; Hohmann, E. L. Enteric pathogens as vaccine vectors for foreign antigen delivery. Infect. Immun. 2004, 72 (10), 5535-47.
52. Schoen, C.; Stritzker, J.; Goebel, W.; Pilgrim, S. Bacteria as DNA vaccine carriers for genetic immunization. Int. J. Med. Microbiol. 2004, 294 (5), 319-35.
53. Roberts, M.; Chatfield, S.; Pickard, D.; Li, J.; Bacon, A. Comparison of abilities of Salmonella enterica serovar typhimurium aroA aroD and aroA htrA mutants to act as live vectors. Infect. Immun. 2000, 68 (10), 6041-3.
54. Hoiseth, S. K.; Stocker, B. A. Aromatic-dependent Salmonella typhimurium are non-virulent and effective as live vaccines. Nature 1981, 291 (5812), 238-9.
55. Darji, A.; Guzman, C. A.; Gerstel, B.; Wachholz, P.; Timmis, K. N.; Wehland, J.; Chakraborty, T.; Weiss, S. Oral somatic transgene vaccination using attenuated Salmonella typhimurium. Cell 1997, 91 (6), 765-75.
56. Evans, D. T.; Chen, L. M.; Gillis, J.; Lin, K. C.; Harty, B.; Mazzara, G. P.; Donis, R. O.; Mansfield, K. G.; Lifson, J. D.; Desrosiers, R. C.; Galan, J. E.; Johnson, R. P. Mucosal priming of simian immunodeficiency virus-specific cytotoxic T-lymphocyte responses in rhesus macaques by the Salmonella type III secretion antigen delivery system. J. Virol. 2003, 77 (4), 2400-9.
57. Hone, D. M.; Tacket, C. O.; Harris, A. M.; Kay, B.; Losonsky, G.; Levine, M. M. Evaluation in volunteers of a candidate live oral attenuated Salmonella typhi vector vaccine. J. Clin. Invest. 1992, 90 (2), 412-20.
58. Gentschev, I.; Dietrich, G.; Spreng, S.; Kolb-Maurer, A.; Daniels, J.; Hess, J.; Kaufmann, S. H.; Goebel, W. Delivery of protein antigens and DNA by virulence-attenuated strains of Salmonella typhimurium and Listeria monocytogenes. J. Biotechnol. 2000, 83 (1-2), 19-26.
59. Yuhua, L.; Kunyuan, G.; Hui, C.; Yongmei, X.; Chaoyang, S.; Xun, T.; Daming, R. Oral cytokine gene therapy against murine tumor using attenuated Salmonella typhimurium. Int. J. Cancer 2001, 94 (3), 438-43.
60. Angelakopoulos, H.; Hohmann, E. L. Pilot study of phoP/phoQ-deleted Salmonella enterica serovar typhimurium expressing Helicobacter pylori urease in adult volunteers. Infect. Immun. 2000, 68 (4), 2135-41.
61. Germanier, R.; Fuer, E. Isolation and characterization of Gal E mutant Ty 21a of Salmonella typhi: A candidate strain for a live, oral typhoid vaccine. J. Infect. Dis. 1975, 131 (5), 553-8.
62. Bumann, D.; Metzger, W. G.; Mansouri, E.; Palme, O.; Wendland, M.; Hurwitz, R.; Haas, G.; Aebischer, T.; von Specht, B. U.; Meyer, T. F. Safety and immunogenicity of live recombinant Salmonella enterica serovar Typhi Ty21a expressing urease A and B from Helicobacter pylori in human volunteers. Vaccine 2001, 20 (5-6), 845-52.
63. Metzger, W. G.; Mansouri, E.; Kronawitter, M.; Diescher, S.; Soerensen, M.; Hurwitz, R.; Bumann, D.; Aebischer, T.; Von Specht, B. U.; Meyer, T. F. Impact of vector-priming on the immunogenicity of a live recombinant Salmonella enterica serovar typhi Ty21a vaccine expressing urease A and B from Helicobacter pylori in human volunteers. Vaccine 2004, 22 (17-18), 2273-7.
64. Kotton, C. N.; Lankowski, A. J.; Scott, N.; Sisul, D.; Chen, L. M.; Raschke, K.; Borders, G.; Boaz, M.; Spentzou, A.; Galan, J. E.; Hohmann, E. L. Safety and immunogenicity of attenuated Salmonella enterica serovar Typhimurium delivering an HIV-1 Gag antigen via the Salmonella Type III secretion system. Vaccine 2006, 24 (37-39), 6216-24.
65. Sizemore, D. R.; Warner, B.; Lawrence, J.; Jones, A.; Killeen, K. P. Live, attenuated Salmonella typhimurium vectoring Campylobacter antigens. Vaccine 2006, 24 (18), 3793-803.
66. Niethammer, A. G.; Xiang, R.; Becker, J. C.; Wodrich, H.; Pertl, U.; Karsten, G.; Eliceiri, B. P.; Reisfeld, R. A. A DNA vaccine against VEGF receptor 2 prevents effective angiogenesis and inhibits tumor growth. Nat. Med. 2002, 8 (12), 1369-75.
67. Lee, C. H.; Wu, C. L.; Shiau, A. L. Endostatin gene therapy delivered by Salmonella choleraesuis in murine tumor models. J. Gene Med. 2004, 6 (12), 1382-93.
68. Darji, A.; zur Lage, S.; Garbe, A. I.; Chakraborty, T.; Weiss, S. Oral delivery of DNA vaccines using attenuated Salmonella typhimurium as carrier. FEMS Immunol. Med. Microbiol. 2000, 27 (4), 341-9.
69. Urashima, M.; Suzuki, H.; Yuza, Y.; Akiyama, M.; Ohno, N.; Eto, Y. An oral CD40 ligand gene therapy against lymphoma using attenuated Salmonella typhimurium. Blood 2000, 95 (4), 1258-63.
70. Weth, R.; Christ, O.; Stevanovic, S.; Zoller, M. Gene delivery by attenuated Salmonella typhimurium: Comparing the efficacy of helper versus cytotoxic T cell priming in tumor vaccination. Cancer Gene Ther. 2001, 8 (8), 599-611.
71. Bowe, F.; Pickard, D. J.; Anderson, R. J.; Londono-Arcila, P.; Dougan, G., Development of attenuated Salmonella strains that express heterologous antigens. Methods Mol. Med. 2003, 87, 83-100.
72. Khan, S. A.; Stratford, R.; Wu, T.; McKelvie, N.; Bellaby, T.; Hindle, Z.; Sinha, K. A.; Eltze, S.; Mastroeni, P.; Pickard, D.; Dougan, G.; Chatfield, S. N.; Brennan, F. R. Salmonella typhi and S. typhimurium derivatives harbouring deletions in aromatic biosynthesis and Salmonella Pathogenicity Island-2 (SPI-2) genes as vaccines and vectors. Vaccine 2003, 21 (5-6), 538-48.
73. Lode, H. N.; Pertl, U.; Xiang, R.; Gaedicke, G.; Reisfeld, R. A. Tyrosine hydroxylase-based DNA-vaccination is effective against murine neuroblastoma. Med. Pediatr. Oncol. 2000, 35 (6), 641-6.
74. Xiang, R.; Lode, H. N.; Chao, T. H.; Ruehlmann, J. M.; Dolman, C. S.; Rodriguez, F.; Whitton, J. L.; Overwijk, W. W.; Restifo, N. P.; Reisfeld, R. A. An autologous oral DNA vaccine protects against murine melanoma. Proc. Natl. Acad. Sci. U.S.A. 2000, 97 (10), 5492-7.
75. Tacket, C. O.; Sztein, M. B.; Wasserman, S. S.; Losonsky, G.; Kotloff, K. L.; Wyant, T. L.; Nataro, J. P.; Edelman, R.; Perry, J.; Bedford, P.; Brown, D.; Chatfield, S.; Dougan, G.; Levine, M. M. Phase 2 clinical trial of attenuated Salmonella enterica serovar typhi oral live vector vaccine CVD 908-htrA in U.S. volunteers. Infect. Immun. 2000, 68 (3), 1196-201.
76. Hohmann, E. L.; Oletta, C. A.; Killeen, K. P.; Miller, S. I. phoP/phoQ-deleted Salmonella typhi (Ty800) is a safe and immunogenic single-dose typhoid fever vaccine in volunteers. J. Infect. Dis. 1996, 173 (6), 1408-14.
77. Hindle, Z.; Chatfield, S. N.; Phillimore, J.; Bentley, M.; Johnson, J.; Cosgrove, C. A.; Ghaem-Maghami, M.; Sexton, A.; Khan, M.; Brennan, F. R.; Everest, P.; Wu, T.; Pickard, D.; Holden, D. W.; Dougan, G.; Griffin, G. E.; House, D.; Santangelo, J. D.; Khan, S. A.; Shea, J. E.; Feldman, R. G.; Lewis, D. J. Characterization of Salmonella enterica derivatives harboring defined aroC and Salmonella pathogenicity island 2 type III secretion system (ssaV) mutations by immunization of healthy volunteers. Infect. Immun. 2002, 70 (7), 3457-67.
78. Kotloff, K. L.; Noriega, F. R.; Samandari, T.; Sztein, M. B.; Losonsky, G. A.; Nataro, J. P.; Picking, W. D.; Barry, E. M.; Levine, M. M. Shigella flexneri 2a strain CVD 1207, with specific deletions in virG, sen, set, and guaBA, is highly attenuated in humans. Infect. Immun. 2000, 68 (3), 1034-9.
79. Kotloff, K. L.; Noriega, F.; Losonsky, G. A.; Sztein, M. B.; Wasserman, S. S.; Nataro, J. P.; Levine, M. M. Safety, immunogenicity, and transmissibility in humans of CVD 1203, a live oral Shigella flexneri 2a vaccine candidate attenuated by deletions in aroA and virG. Infect. Immun. 1996, 64 (11), 4542-8.
80. Katz, D. E.; Coster, T. S.; Wolf, M. K.; Trespalacios, F. C.; Cohen, D.; Robins, G.; Hartman, A. B.; Venkatesan, M. M.; Taylor, D. N.; Hale, T. L. Two studies evaluating the safety and immunogenicity of a live, attenuated Shigella flexneri 2a vaccine (SC602) and excretion of vaccine organisms in North American volunteers. Infect. Immun. 2004, 72 (2), 923-30.
81. Xu, F.; Hong, M.; Ulmer, J. B. Immunogenicity of an HIV-1 gag DNA vaccine carried by attenuated Shigella. Vaccine 2003, 21 (7-8), 644-8.
82. Sizemore, D. R.; Branstrom, A. A.; Sadoff, J. C. Attenuated bacteria as a DNA delivery vehicle for DNA-mediated immunization. Vaccine 1997, 15 (8), 804-7.
83. + T cells and antiviral protective immunity. J. Virol. 2001, 75 (20), 9665-70.
84. Fennelly, G. J.; Khan, S. A.; Abadi, M. A.; Wild, T. F.; Bloom, B. R. Mucosal DNA vaccine immunization against measles with a highly attenuated Shigella flexneri vector. J. Immunol. 1999, 162 (3), 1603-10.
85. Kotloff, K. L.; Pasetti, M. F.; Barry, E. M.; Nataro, J. P.; Wasserman, S. S.; Sztein, M. B.; Picking, W. D.; Levine, M. M. Deletion in the Shigella enterotoxin genes further attenuates Shigella flexneri 2a bearing guanine auxotrophy in a phase 1 trial of CVD 1204 and CVD 1208. J. Infect. Dis. 2004, 190 (10), 1745-54.
86. Anderson, R. J.; Pasetti, M. F.; Sztein, M. B.; Levine, M. M.; Noriega, F. R. DeltaguaBA attenuated Shigella flexneri 2a strain CVD 1204 as a Shigella vaccine and as a live mucosal delivery system for fragment C of tetanus toxin. Vaccine 2000, 18 (21), 2193-202.
87. Barry, E. M.; Altboum, Z.; Losonsky, G.; Levine, M. M. Immune responses elicited against multiple enterotoxigenic Escherichia coli fimbriae and mutant LT expressed in attenuated Shigella vaccine strains. Vaccine 2003, 21 (5-6), 333-40.
88. Altboum, Z.; Barry, E. M.; Losonsky, G.; Galen, J. E.; Levine, M. M. Attenuated Shigella flexneri 2a Delta guaBA strain CVD 1204 expressing enterotoxigenic Escherichia coli (ETEC) CS2 and CS3 fimbriae as a live mucosal vaccine against Shigella and ETEC infection. Infect. Immun. 2001, 69 (5), 3150-8.
89. Koprowski, H., II; Levine, M. M.; Anderson, R. J.; Losonsky, G.; Pizza, M.; Barry, E. M. Attenuated Shigella flexneri 2a vaccine strain CVD 1204 expressing colonization factor antigen I and mutant heat-labile enterotoxin of enterotoxigenic Escherichia coli. Infect. Immun. 2000, 68 (9), 4884-92.
90. Pasetti, M. F.; Barry, E. M.; Losonsky, G.; Singh, M.; Medina-Moreno, S. M.; Polo, J. M.; Ulmer, J.; Robinson, H.; Sztein, M. B.; Levine, M. M. Attenuated Salmonella enterica serovar Typhi and Shigella flexneri 2a strains mucosally deliver DNA vaccines encoding measles virus hemagglutinin, inducing specific immune responses and protection in cotton rats. J. Virol. 2003, 77 (9), 5209-17.
91. Zheng, J. P.; Zhang, Z. S.; Li, S. Q.; Liu, X. X.; Yuan, S. L.; Wang, P.; Zhan, D. W.; Wang, L. C.; Huang, C. F. Construction of a novel Shigella live-vector strain co-expressing CS3 and LTB/STm of enterotoxigenic E. coli. World J. Gastroenterol. 2005, 11 (22), 3411-8.
92. Cossart, P.; Mengaud, J. Listeria monocytogenes. A model system for the molecular study of intracellular parasitism. Mol. Biol. Med. 1989, 6 (5), 463-74.
93. Portnoy, D. A.; Chakraborty, T.; Goebel, W.; Cossart, P. Molecular determinants of Listeria monocytogenes pathogenesis. Infect. Immun. 1992, 60 (4), 1263-7.
94. de Chastellier, C.; Berche, P. Fate of Listeria monocytogenes in murine macrophages: Evidence for simultaneous killing and survival of intracellular bacteria. Infect. Immun. 1994, 62 (2), 543-53.
95. Finlay, B. B.; Cossart, P. Exploitation of mammalian host cell functions by bacterial pathogens. Science 1997, 276 (5313), 718-25.
96. Pilgrim, S.; Stritzker, J.; Schoen, C.; Kolb-Maurer, A.; Geginat, G.; Loessner, M. J.; Gentschev, I.; Goebel, W. Bactofection of mammalian cells by Listeria monocytogenes: Improvement and mechanism of DNA delivery. Gene Ther. 2003, 10 (24), 2036-45.
97. Pan, Z. K.; Ikonomidis, G.; Lazenby, A.; Pardoll, D.; Paterson, Y. A recombinant Listeria monocytogenes vaccine expressing a model tumour antigen protects mice against lethal tumour cell challenge and causes regression of established tumours. Nat. Med. 1995, 1 (5), 471-7.
98. Weiskirch, L. M.; Pan, Z. K.; Paterson, Y. The tumor recall response of antitumor immunity primed by a live, recombinant Listeria monocytogenes vaccine comprises multiple effector mechanisms. Clin. Immunol. 2001, 98 (3), 346-57.
99. Paglia, P.; Arioli, I.; Frahm, N.; Chakraborty, T.; Colombo, M. P.; Guzman, C. A. The defined attenuated Listeria monocytogenes delta mp12 mutant is an effective oral vaccine carrier to trigger a long-lasting immune response against a mouse fibrosarcoma. Eur. J. Immunol. 1997, 27 (6), 1570-5.
100. Gunn, G. R.; Zubair, A.; Peters, C.; Pan, Z. K.; Wu, T. C.; Paterson, Y. Two Listeria monocytogenes vaccine vectors that express different molecular forms of human papilloma virus-16 (HPV-16) E7 induce qualitatively different T cell immunity that correlates with their ability to induce regression of established tumors immortalized by HPV-16. J. Immunol. 2001, 167 (11), 6471-9.
101. Liau, L. M.; Jensen, E. R.; Kremen, T. J.; Odesa, S. K.; Sykes, S. N.; Soung, M. C.; Miller, J. F.; Bronstein, J. M. Tumor immunity within the central nervous system stimulated by recombinant Listeria monocytogenes vaccination. Cancer Res. 2002, 62 (8), 2287-93.
102. Angelakopoulos, H.; Loock, K.; Sisul, D. M.; Jensen, E. R.; Miller, J. F.; Hohmann, E. L. Safety and shedding of an attenuated strain of Listeria monocytogenes with a deletion of actA/plcB in adult volunteers: A dose escalation study of oral inoculation. Infect. Immun. 2002, 70 (7), 3592-601.
103. Verch, T.; Pan, Z. K.; Paterson, Y. Listeria monocytogenes-based antibiotic resistance gene-free antigen delivery system applicable to other bacterial vectors and DNA vaccines. Infect. Immun. 2004, 72 (11), 6418-25.
104. Brockstedt, D. G.; Giedlin, M. A.; Leong, M. L.; Bahjat, K. S.; Gao, Y.; Luckett, W.; Liu, W.; Cook, D. N.; Portnoy, D. A.; Dubensky, T. W., Jr. Listeria-based cancer vaccines that segregate immunogenicity from toxicity. Proc. Natl. Acad. Sci. U.S.A. 2004, 101 (38), 13832-7.
105. Peng, X.; Hussain, S. F.; Paterson, Y. The ability of two Listeria monocytogenes vaccines targeting human papillomavirus-16 E7 to induce an antitumor response correlates with myeloid dendritic cell function. J. Immunol. 2004, 172 (10), 6030-8.
106. Miki, K.; Nagata, T.; Tanaka, T.; Kim, Y. H.; Uchijima, M.; Ohara, N.; Nakamura, S.; Okada, M.; Koide, Y. Induction of protective cellular immunity against Mycobacterium tuberculosis by recombinant attenuated self-destructing Listeria monocytogenes strains harboring eukaryotic expression plasmids for antigen 85 complex and MPB/MPT51. Infect. Immun. 2004, 72 (4), 2014-21.
107. Mata, M.; Yao, Z. J.; Zubair, A.; Syres, K.; Paterson, Y. Evaluation of a recombinant Listeria monocytogenes expressing an HIV protein that protects mice against viral challenge. Vaccine 2001, 19 (11-12), 1435-45.
108. Soussi, N.; Saklani-Jusforgues, H.; Colle, J. H.; Milon, G.; Glaichenhaus, N.; Goossens, P. L. Effect of intragastric and intraperitoneal immunisation with attenuated and wild-type LACK-expressing Listeria monocytogenes on control of murine Leishmania major infection. Vaccine 2002, 20 (21-22), 2702-12.
109. Peters, C.; Peng, X.; Douven, D.; Pan, Z. K.; Paterson, Y. The induction of HIV Gag-specific CD8+ T cells in the spleen and gut-associated lymphoid tissue by parenteral or mucosal immunization with recombinant Listeria monocytogenes HIV Gag. J. Immunol. 2003, 170 (10), 5176-87.
110. Souders, N. C.; Verch, T.; Paterson, Y. In vivo bactofection: Listeria can function as a DNA-cancer vaccine. DNA Cell Biol. 2006, 25 (3), 142-51.
111. Saklani-Jusforgues, H.; Fontan, E.; Soussi, N.; Milon, G.; Goossens, P. L. Enteral immunization with attenuated recombinant Listeria monocytogenes as a live vaccine vector: Organ-dependent dynamics of CD4 T lymphocytes reactive to a Leishmania major tracer epitope. Infect. Immun. 2003, 71 (3), 1083-90.
112. Tvinnereim, A. R.; Hamilton, S. E.; Harty, J. T. CD8(+)-T-cell response to secreted and nonsecreted antigens delivered by recombinant Listeria monocytogenes during secondary infection. Infect. Immun. 2002, 70 (1), 153-62.
113. Starks, H.; Bruhn, K. W.; Shen, H.; Barry, R. A.; Dubensky, T. W.; Brockstedt, D.; Hinrichs, D. J.; Higgins, D. E.; Miller, J. F.; Giedlin, M.; Bouwer, H. G. Listeria monocytogenes as a vaccine vector: Virulence attenuation or existing antivector immunity does not diminish therapeutic efficacy. J. Immunol. 2004, 173 (1), 420-7.
114. Loeffler, D. I.; Schoen, C. U.; Goebel, W.; Pilgrim, S. Comparison of different live vaccine strategies in vivo for delivery of protein antigen or antigen-encoding DNA and mRNA by virulence-attenuated Listeria monocytogenes. Infect. Immun. 2006, 74 (7), 3946-57.
115. Ryan, E. T.; Calderwood, S. B. Cholera vaccines. Clin. Infect. Dis. 2000, 31 (2), 561-5.
116. Ryan, E. T.; Crean, T. I.; John, M.; Butterton, J. R.; Clements, J. D.; Calderwood, S. B. In vivo expression and immunoadjuvancy of a mutant of heat-labile enterotoxin of Escherichia coli in vaccine and vector strains of Vibrio cholerae. Infect. Immun. 1999, 67 (4), 1694-701.
117. Ryan, E. T.; Crean, T. I.; Kochi, S. K.; John, M.; Luciano, A. A.; Killeen, K. P.; Klose, K. E.; Calderwood, S. B. Development of a DeltaglnA balanced lethal plasmid system for expression of heterologous antigens by attenuated vaccine vector strains of Vibrio cholerae. Infect. Immun. 2000, 68 (1), 221-6.
118. Russmann, H.; Gerdemann, U.; Igwe, E. I.; Panthel, K.; Heesemann, J.; Garbom, S.; Wolf-Watz, H.; Geginat, G. Attenuated Yersinia pseudotuberculosis carrier vaccine for simultaneous antigen-specific CD4 and CD8 T-cell induction. Infect. Immun. 2003, 71 (6), 3463-72.
119. Gundel, I.; Weidinger, G.; ter Meulen, V.; Heesemann, J.; Russmann, H.; Niewiesk, S. Oral immunization with recombinant Yersinia enterocolitica expressing a measles virus CD4 T cell epitope protects against measles virus-induced encephalitis. J. Gen. Virol. 2003, 84 (Part 4), 775-9.
120. Al-Mariri, A.; Tibor, A.; Lestrate, P.; Mertens, P.; De Bolle, X.; Letesson, J. J. Yersinia enterocolitica as a vehicle for a naked DNA vaccine encoding Brucella abortus bacterioferritin or P39 antigen. Infect. Immun. 2002, 70 (4), 1915-23.
121. Wiedig, C. A.; Kramer, U.; Garbom, S.; Wolf-Watz, H.; Autenrieth, I. B. Induction of CD8+ T cell responses by Yersinia vaccine carrier strains. Vaccine 2005, 23 (42), 4984-98.
122. Stevenson, A.; Roberts, M. Use of Bordetella bronchiseptica and Bordetella pertussis as live vaccines and vectors for heterologous antigens. FEMS Immunol. Med. Microbiol. 2003, 37 (2-3), 121-8.
123. Starke, J. R.; Connelly, K. K. Bacille Calmette-Guerin vaccine. In Vaccines; Plotkin, S., Mortimer, E. A., Eds.; Saunders Co.: Philadelphia, 1994.
124. Edelman, R.; Palmer, K.; Russ, K. G.; Secrest, H. P.; Becker, J. A.; Bodison, S. A.; Perry, J. G.; Sills, A. R.; Barbour, A. G.; Luke, C. J.; Hanson, M. S.; Stover, C. K.; Burlein, J. E.; Bansal, G. P.; Connor, E. M.; Koenig, S. Safety and immunogenicity of recombinant Bacille Calmette-Guerin (rBCG) expressing Borrelia burgdorferi outer surface protein A (OspA) lipoprotein in adult volunteers: A candidate Lyme disease vaccine. Vaccine 1999, 17 (7-8), 904-14.
125. Lee, S. F. Oral colonization and immune responses to Streptococcus gordonii: Potential use as a vector to induce antibodies against respiratory pathogens. Curr. Opin. Infect. Dis. 2003, 16 (3), 231-5.
126. Grangette, C.; Muller-Alouf, H.; Geoffroy, M.; Goudercourt, D.; Turneer, M.; Mercenier, A. Protection against tetanus toxin after intragastric administration of two recombinant lactic acid bacteria: Impact of strain viability and in vivo persistence. Vaccine 2002, 20 (27-28), 3304-9.
127. Miyoshi, A.; Bermudez-Humaran, L. G.; Ribeiro, L. A.; Le Loir, Y.; Oliveira, S. C.; Langella, P.; Azevedo, V., Heterologous expression of Brucella abortus GroEL heat-shock protein in Lactococcus lactis. Microb. Cell Fact. 2006, 5, 14.
128. Vemulapalli, R.; He, Y.; Boyle, S. M.; Sriranganathan, N.; Schurig, G. G. Brucella abortus strain RB51 as a vector for heterologous protein expression and induction of specific Th1 type immune responses. Infect. Immun. 2000, 68 (6), 3290-6.
129. Shimoji, Y.; Oishi, E.; Kitajima, T.; Muneta, Y.; Shimizu, S.; Mori, Y. Erysipelothrix rhusiopathiae YS-1 as a live vaccine vehicle for heterologous protein expression and intranasal immunization of pigs. Infect. Immun. 2002, 70 (1), 226-32.
130. Ducle, H.; Hong, H. A.; Fairweather, N.; Ricca, E.; Cutting, S. M. Bacterial spores as vaccine vehicles. Infect. Immun. 2003, 71 (5), 2810-8.
131. Geoffroy, C.; Gaillard, J. L.; Alouf, J. E.; Berche, P. Purification, characterization, and toxicity of the sulfhydryl-activated hemolysin listeriolysin O from Listeria monocytogenes. Infect. Immun. 1987, 55 (7), 1641-6.
132. Bielecki, J.; Youngman, P.; Connelly, P.; Portnoy, D. A. Bacillus subtilis expressing a haemolysin gene from Listeria monocytogenes can grow in mammalian cells. Nature 1990, 345 (6271), 175-6.
133. Ikonomidis, G.; Paterson, Y.; Kos, F. J.; Portnoy, D. A. Delivery of a viral antigen to the class I processing and presentation pathway by Listeria monocytogenes. J. Exp. Med. 1994, 180 (6), 2209-18.
134. Kayal, S.; Charbit, A. Listeriolysin O: A key protein of Listeria monocytogenes with multiple functions. FEMS Microbiol. Rev. 2006, 30 (4), 514-29.
135. Isberg, R. R.; Voorhis, D. L.; Falkow, S. Identification of invasin: A protein that allows enteric bacteria to penetrate cultured mammalian cells. Cell 1987, 50 (5), 769-78.
136. Isberg, R. R.; Van Nhieu, G. T. The mechanism of phagocytic uptake promoted by invasin-integrin interaction. Trends Cell Biol. 1995, 5 (3), 120-4.
137. Lecuit, M.; Ohayon, H.; Braun, L.; Mengaud, J.; Cossart, P. Internalin of Listeria monocytogenes with an intact leucine-rich repeat region is sufficient to promote internalization. Infect. Immun. 1997, 65 (12), 5309-19.
138. Gaillard, J. L.; Berche, P.; Frehel, C.; Gouin, E.; Cossart, P. Entry of L. monocytogenes into cells is mediated by internalin, a repeat protein reminiscent of surface antigens from gram-positive cocci. Cell 1991, 65 (7), 1127-41.
139. Osiecki, J. C.; Barker, J.; Picking, W. L.; Serfis, A. B.; Berring, E.; Shah, S.; Harrington, A.; Picking, W. D. IpaC from Shigella and SipC from Salmonella possess similar biochemical properties but are functionally distinct. Mol. Microbiol. 2001, 42 (2), 469-81.
140. Hayward, R. D.; Cain, R. J.; McGhie, E. J.; Phillips, N.; Garner, M. J.; Koronakis, V. Cholesterol binding by the bacterial type III translocon is essential for virulence effector delivery into mammalian cells. Mol. Microbiol. 2005, 56 (3), 590-603.
141. Castagliuolo, I.; Beggiao, E.; Brun, P.; Barzon, L.; Goussard, S.; Manganelli, R.; Grillot-Courvalin, C.; Palu, G. Engineered E. coli delivers therapeutic genes to the colonic mucosa. Gene Ther. 2005, 12 (13), 1070-8.
142. Laner, A.; Goussard, S.; Ramalho, A. S.; Schwarz, T.; Amaral, M. D.; Courvalin, P.; Schindelhauer, D.; Grillot-Courvalin, C. Bacterial transfer of large functional genomic DNA into human cells. Gene Ther. 2005, 12 (21), 1559-72.
143. Fajac, I.; Grosse, S.; Collombet, J. M.; Thevenot, G.; Goussard, S.; Danel, C.; Grillot-Courvalin, C. Recombinant Escherichia coli as a gene
144. Grillot-Courvalin, C.; Goussard, S.; Huetz, F.; Ojcius, D. M.; Courvalin, P. Functional gene transfer from intracellular bacteria to mammalian cells. Nat. Biotechnol. 1998, 16 (9), 862-6.
145. Sorensen, H. P.; Mortensen, K. K. Advanced genetic strategies for recombinant protein expression in Escherichia coli. J. Biotechnol. 2005, 115 (2), 113-28.
146. Balbas, P.; Bolivar, F. Back to basics: pBR322 and protein expression systems in E. coli. Methods Mol. Biol. 2004, 267, 77-90.
147. Guzman, C. A.; Domann, E.; Rohde, M.; Bruder, D.; Darji, A.; Weiss, S.; Wehland, J.; Chakraborty, T.; Timmis, K. N. Apoptosis of mouse dendritic cells is triggered by listeriolysin, the major virulence determinant of Listeria monocytogenes. Mol. Microbiol. 1996, 20 (1), 119-26.
148. Baneyx, F. Recombinam protein expression in Escherichia coli. Curr. Opin. Biotechnol. 1999, 10 (5), 411-21.
149. Bubert, A.; Sokolovic, Z.; Chun, S. K.; Papatheodorou, L.; Simm, A.; Goebel, W. Differential expression of Listeria monocytogenes virulence genes in mammalian host cells. Mol. Gen. Genet. 1999, 261 (2), 323-36.
150. Gentschev, I.; Dietrich, G.; Spreng, S.; Neuhaus, B.; Maier, E.; Benz, R.; Goebel, W.; Fensterle, J.; Rapp, U. R. Use of the α-hemolysin secretion system of Escherichia coli for antigen delivery in the Salmonella typhi Ty21a vaccine strain. Int. J. Med. Microbiol. 2004, 294 (6), 363-71.
151. Shen, H.; Miller, J. F.; Fan, X.; Kolwyck, D.; Ahmed, R.; Harty, J. T. Compartmentalization of bacterial antigens: Differential effects on priming of CD8 T cells and protective immunity. Cell 1998, 92 (4), 535-45.
152. Nishikawa, H.; Sato, E.; Briones, G.; Chen, L. M.; Matsuo, M.; Nagata, Y.; Ritter, G.; Jager, E.; Nomura, H.; Kondo, S.; Tawara, I.; Kato, T.; Shiku, H.; Old, L. J.; Galan, J. E.; Gnjatic, S. In vivo antigen delivery by a Salmonella typhimurium type III secretion system for therapeutic cancer vaccines. J. Clin. Invest. 2006, 116 (7), 1946-54.
153. Cornelis, G. R. The type III secretion injectisome. Nat. Rev. Microbiol. 2006, 4 (11), 811-25.
154. Finlay, B. B.; McFadden, G. Anti-immunology: Evasion of the host immune system by bacterial and viral pathogens. Cell 2006, 124 (4), 767-82.
155. Isticato, R.; Cangiano, G.; Tran, H. T.; Ciabattini, A.; Medaglini, D.; Oggioni, M. R.; De Felice, M.; Pozzi, G.; Ricca, E. Surface display of recombinant proteins on Bacillus subtilis spores. J. Bacteriol. 2001, 183 (21), 6294-301.
156. Mauriello, E. M.; Ducle, H.; Isticato, R.; Cangiano, G.; Hong, H. A.; De Felice, M.; Ricca, E.; Cutting, S. M. Display of heterologous antigens on the Bacillus subtilis spore coat using CotC as a fusion partner. Vaccine 2004, 22 (9-10), 1177-87.
157. Munkonge, F. M.; Dean, D. A.; Hillery, E.; Griesenbach, U.; Alton, E. W. Emerging significance of plasmid DNA nuclear import in gene therapy. Adv. Drug Delivery Rev. 2003, 55 (6), 749-60.
158. Whittaker, G. R. Virus nuclear import. Adv. Drug Delivery Rev. 2003, 55 (6), 733-47.
159. Pouton, C. W. Nuclear import of polypeptides, polynucleotides and supramolecular complexes. Adv. Drug Delivery Rev. 1998, 34 (1), 51-64.
160. Leenhouts, C. J.; Ramasamy, R.; Steen, A.; Kok, J.; Buist, G.; Kuipers, O. P. (Applied Nanosystems B.V.). Method to provide bacterial ghosts provided with antigens. U.S. Patent 7,067,639, 2006.
161. Shiloach, J.; Fass, R. Growing E. coli to high cell density: A historical perspective on method development. Biotechnol. Adv. 2005, 23 (5), 345-57.
162. Monteiro, S. M.; Clemente, J. J.; Henriques, A. O.; Gomes, R. J.; Carrondo, M. J.; Cunha, A. E. A procedure for high-yield spore production by Bacillus subtilis. Biotechnol. Prog. 2005, 21 (4), 1026-31.
163. Swartz, J. R. Escherichia coli Recombinant DNA Technology. In Escherichia coli and Salmonella typhimurium: Cellular and Molecular Biology, 2nd ed.; Neidhardt, F. C., Ed.; American Society for Microbiology: Washington, DC, 1987; Vol. 2.
164. Shiloach, J.; Bauer, S. High yield growth of E. coli at different temperatures in a bench scale fermenter. Biotechnol. Bioeng. 1975, 17, 227-39.
165. Nakano, K.; Rischke, M.; Sato, S.; Markl, H. Influence of acetic acid on the growth of Escherichia coli K12 during high-cell-density cultivation in a dialysis reactor. Appl. Microbiol. Biotechnol. 1997, 48 (5), 597-601.
166. Plotkin, S. A. Vaccines: Past, present and future. Nat. Med. 2005, 11 (Suppl. 4), S5-11.
167. Corbel, M. J. Reasons for instability of bacterial vaccines. Dev. Biol. Stand. 1996, 87, 113-24.
168. Zaffran, M. Vaccine transport and storage: Environmental Challenges. In New Approaches to Stabilization of Vaccine Potency; Brown, F., Ed.; Karger: Basel, Switzerland, 1996.
169. Lloyd, J. S. Improving the cold chain for vaccines. WHO Chron. 1977, 31 (13).
170. John, T. J. Vaccine stability in the context of vaccine deliver in a developing country: India. In New Approaches to Stabilization of Vaccine Potency; Brown, F., Ed.; Karger: Basel, Switzerland, 1996.
171. Burke, C. J.; Hsu, T. A.; Volkin, D. B. Formulation, stability, and delivery of live attenuated vaccines for human use. Crit. Rev. Ther. Drug Carrier Syst. 1999, 16 (1), 1-83.
172. Potts, M. Desiccation tolerance of prokaryotes. Microbiol. Rev. 1994, 58 (4), 755-805.
173. Mathias, S. F.; Franks, F.; Hatley, R. H. M. The stabilization of proteins by freeze-drying and by alternative methods. In Polypeptide and Protein Drugs: Production, Characterization, and Formulation; Hider, R. C., Barlow, D., Eds.; Ellis Horwood: New York, 1991.
174. Crowe, J. H.; Crowe, L. M.; Carpenter, J. F. Preserving dry biomaterials: The water replacement hypothesis, Part 1. BioPharm 1993 (April), 28.
175. de Castro, A. G.; Lapinski, J.; Tunnacliffe, A. Anhydrobiotic engineering. Nat. Biotechnol. 2000, 18 (5), 473.
176. Garcia De Castro, A.; Bredholt, H.; Strom, A. R.; Tunnacliffe, A. Anhydrobiotic engineering of gram-negative bacteria. Appl. Environ. Microbiol. 2000, 66 (9), 4142-4.
177. Billi, D.; Wright, D. J.; Helm, R. F.; Prickett, T.; Potts, M.; Crowe, J. H. Engineering desiccation tolerance in Escherichia coli. Appl. Environ. Microbiol. 2000, 66 (4), 1680-4.
178. Paccez, J. D.; Luiz, W. B.; Sbrogio-Almeida, M. E.; Ferreira, R. C.; Schumann, W.; Ferreira, L. C. Stable episomal expression system under control of a stress inducible promoter enhances the immunogenicity of Bacillus subtilis as a vector for antigen delivery. Vaccine 2006, 24 (15), 2935-43.
179. Oggioni, M. R.; Ciabattini, A.; Cuppone, A. M.; Pozzi, G. Bacillus spores for vaccine delivery. Vaccine 2003, 21 (Suppl. 2), S96-101.
180. Piggot, P. J.; Hilbert, D. W. Sporulation of Bacillus subtilis. Curr. Opin. Microbiol. 2004, 7 (6), 579-86.
181. Nicholson, W. L.; Setlow, P. Sporulation, germination and outgrowth. In Molecular biological methods for bacillus; Harwood, C. R., Cutting, S. M., Eds.; Wiley: Chichester, U.K., 1990; pp 391-450.